Trending Topic

Acute myeloid leukaemia
3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

Myeloma

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

Dr. Miguel-Angel Perales discusses the need to expand access to CAR T-cell therapy by increasing awareness among community physicians. Real-world data show comparable or improved outcomes compared to trials, even in older and sicker patients, underscoring the importance of timely referrals for this innovative cancer treatment.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and ...

55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS
Prof. Katja Weisel, Dr Nisha Joseph, Prof. Roman Hájek

Three experts discuss data presented at ASH 2024 on BCMA-targeting agents in multiple myeloma.

Mark CompleteCompleted
BookmarkBookmarked

With the the 66th ASH Annual Meeting & Exposition still fresh in our minds, Dr Rahul Banerjee (Fred Hutch Cancer Center, Seattle, WA, USA) and Dr Samer Al Hadidi (University of Arkansas for Medical Sciences, Little Rock, AR, USA) outline ...

9 mins
Sponsored Content

Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.

Summary of Product Characteristics Link here
55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS
Prof. María-Victoria Mateos, Dr Rakesh Popat, Prof. Evangelos Terpos

Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.

Mark CompleteCompleted
BookmarkBookmarked

The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.

Mark CompleteCompleted
BookmarkBookmarked

We’re looking forward to the EHA 2024 Hybrid Congress which is taking place in Madrid, between 13-16 June 2024.  Promising attendees the opportunity to explore the latest advancements in haematology, including cutting-edge technologies, treatments, and products. The focus will encompass a ...

32 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Prof. Cristina Gasparetto, Prof. Sagar Lonial, Prof. Sundar Jagannath

Learn about investigational protein degradation and immunomodulatory therapies in multiple myeloma.

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).

22 mins

Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.

Load More...
Close Popup